Product news

Share this article:
The FDA has approved Novo Nordisk's PrandiMet, a combination of the insulin secretagogue repaglinide and metformin for the treatment of type 2 diabetes. 
 
Pasteur, the vaccines division of the Sanofi-Aventis Group, announced that the FDA has licensed Pentacel, a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b. Pentacel vaccine is approved for use in infants and children 6 weeks through 4 years of age (prior to age 5). 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions